What is Entresto?
Entresto is a medication used for the treatment of heart failure with reduced ejection fraction. It is a combination drug made up of sacubitril and valsartan. Sacubitril works by inhibiting neprilysin, a protein that breaks down several beneficial hormones. Valsartan is an angiotensin receptor blocker (ARB) that works by relaxing the blood vessels and decreasing the amount of work the heart has to do to pump blood.
Entresto is known to reduce morbidity and mortality in patients with heart failure compared to traditional ACE inhibitors such as lisinopril. FDA approval for Entresto was granted in July 2015, making it the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) approved for use in patients with chronic heart failure. In 2021, the drug was also approved for the treatment of heart failure patients with ejection fraction below normal.
As with any medication, Entresto can have side effects. Common side effects include dizziness, cough, low blood pressure, and high levels of potassium in the blood. Patients with a history of angioedema, a type of allergic reaction, should not take Entresto. It is important to inform your doctor of any other medications you are taking to avoid potential drug interactions.
In 2019, Novartis, the manufacturer of Entresto, had a revenue increase due to the rising sales of the medication. However, in 2021, Novartis was investigated by US federal prosecutors for their marketing practices for Entresto.
Overall, Entresto is an effective medication for the treatment of heart failure with reduced ejection fraction. It is important to discuss any questions or concerns with your doctor before starting any new medications.
Frequently Asked Questions about entresto
Entresto is used to treat heart failure in adults. Entresto has been shown to lower the risk of cardiovascular related deaths and heart failure related hospitalisation.
Entresto has a boxed warning . This is the most serious warning from the Food and Drug Administration (FDA). A boxed warning alerts doctors and patients about drug effects that may be dangerous. Taking Entresto while you're pregnant can cause fetal toxicity, which is a type of fetal harm.
Entresto (sacubitril/valsartan) is used to treat people with long-lasting (chronic) heart failure. Together with other heart failure medications, it can improve the heart's pumping function and can lower the chances of needing to go to the hospital or dying from heart failure.
Patient Information ENTRESTO (en-TRESS-toh) (sacubitril and valsartan) tablets What is the most important information I should know about ENTRESTO? ENTRESTO can harm or cause death to your unborn baby. Talk to your doctor about other ways to treat heart failure if you plan to become pregnant.
Key Points. Entresto has been shown to increase left ventricular ejection fraction (LVEF), the volume of blood that your left ventricle pumps out of your heart when it contracts. This helps to supply more blood and oxygen to your body.
In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, concomitant use of NSAIDs, including COX-2 inhibitors, with Entresto may result in worsening of renal function, including possible acute renal failure. These effects are usually reversible.
Entresto is a medication that may help those with heart failure. It can be prescribed to help improve the heart's ejection fraction. Although the FDA has approved this medication, side effects are possible. In rare cases, serious complications such as kidney failure and fetal toxicity can occur.
Side effect specifics
- Low blood pressure. You may develop low blood pressure from taking Entresto.
- Allergic reaction. As with most drugs, Entresto can cause an allergic reaction in some people.
- Dizziness. You may experience dizziness during your treatment with Entresto.
- Kidney problems.
- Cough.
Some products that may interact with this medication include: aliskiren, lithium, drugs that may increase the level of potassium in the blood (such as sparsentan, ACE inhibitors including benazepril/lisinopril, birth control pills containing drospirenone).
How much can Entresto increase your ejection fraction? The PROVE-HF trial showed a median increase in left ventricular ejection fraction from 28.2% to 37.8% at 12 months. A significant 5.2% increase was seen in 6 months.
Researchers from Brigham and Women's Hospital found that heart failure patients with reduced ejection fraction treated with Entresto (sacubitril-valsartan) have a projected increased life expectancy of one and a half to two years, as compared to those treated with Vasotec (enalapril), the current standard of care in ...
Researchers from Brigham and Women's Hospital found that heart failure patients with reduced ejection fraction treated with Entresto (sacubitril-valsartan) have a projected increased life expectancy of one and a half to two years, as compared to those treated with Vasotec (enalapril), the current standard of care in ...
Studies have shown that Entresto is effective at improving ejection fraction. It is frequently given with other heart failure medications in place of an ACE inhibitor or ARB.
Researchers from Brigham and Women's Hospital found that heart failure patients with reduced ejection fraction treated with Entresto (sacubitril-valsartan) have a projected increased life expectancy of one and a half to two years, as compared to those treated with Vasotec (enalapril), the current standard of care in ...
